bioMérieux – 2025 Financial Results

Marcy-l’Etoile (France), February 27, 2026 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on February 26 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial statements for the year ending December 31, 2025.

Key highlights:

¤ Full year sales reaching €4,070 million, representing +6.2% organic sales growth, driven by a 9.4% organic increase across the four growth drivers of the GO•28 strategic plan:

• BIOFIRE^® non-respiratory panels delivered 10% organic sales growth, reaching €598 million, supported by increased sales across all panels and a net expansion of the installed base by 1,800 units (versus +1,350 in 2024);
• SPOTFIRE^® generated €168 million in sales, representing an 84% increase in value and more than 100% in volumes. The installed base reached 6,400 instruments at year-end, a 110% increase versus 2024;
• Microbiology delivered 4% organic growth, a performance negatively impacted by a double-digit decline in China; excluding this geography, Microbiology grew 6.3%;
• Industrial Applications achieved robust growth with +9% organic sales increase, fueled notably by 14% organic sales growth in the Pharma Quality Control segment.

¤ BIOFIRE^® respiratory panels sales rose by 1% organically, reflecting an epidemiology trend in 2025 broadly in line with the prior year.

¤ Q4 25 organic sales growth reached 3.5%, impacted by a mid-single digit organic decrease in China and a 10% organic decline in BIOFIRE^® Respiratory Panels sales on a high comparison base. The four GO•28 growth drivers sales grew +10% organically during the quarter.

¤ In 2025, contributive operating income before non-recurring items (CEBIT) reached €728 million, up 16% at constant exchange rates and scope, and up 8% on a reported basis, reflecting the proper execution of GO•28 strategic plan on sales growth and efficiency improvements. The reported CEBIT margin rose to 17.9% of sales, an improvement of close to 160 basis points at constant exchange rates and scope versus 2024.

¤ Net income (group share) amounted to €398 million, down 8% compared to 2024, impacted by the partial impairment of the VITEK^® REVEAL™ technology.

¤ Adjusted diluted earnings per share (Adjusted EPS) of €4.64, +9% versus the previous year.

¤ 2026 Guidance:

• Sales are expected to grow between +5% and +7% at constant exchange rates and scope, in line with GO•28 growth ambitions;
• Contributive operating income before non-recurring items is expected to grow by at least 10% at constant exchange rates and scope. A negative currency effect estimated between €50 million to €60 million versus 2025 is expected in 2026.

¤ Confirmation of the GO•28 strategic plan ambitions to grow sales by +7% CAGR at constant exchange rate and scope over the period 2024/2028, and to grow CEBIT by at least +10% year on year to 2028 at constant exchange rates and scope, leading to an improvement of around 500bps of the CEBIT margin at constant exchange rates and scope over the period, while acting responsibly, with renewed and more ambitious CSR targets. 

Pierre Boulud, Chief Executive Officer, says: “After two years of implementation, we are exceeding the ambitions of the GO•28 strategic plan across all dimensions — profitable growth, Corporate Social Responsibility and employee engagement — thanks to the great dedication of our teams. At the same time, we have continued to invest in the future through promising acquisitions (SpinChip, Accellix, Day Zero Diagnostics) and a sustained focus on innovation, with multiple product launches in 2025. Building on 2025 solid results exceeding the overall diagnostics market growth, we expect, for 2026, our sales to grow between +5% and +7% at constant exchange rate and scope and our CEBIT to increase by at least 10% at constant exchange rate and scope.”